Xtant Medical reports 28% revenue growth in FY2024; guides FY2025 revenue $126M-$130M

Xtant Medical Holdings, Inc.

Revenue $117.3M FY2024, up 28% YoY; Q4 revenue $31.5M, up 12%.
Net loss FY2024 $16.4M ($0.12/share) vs prior year net income $660k (incl $11.7M bargain gain).
Adjusted EBITDA loss FY2024 $2.3M vs loss $1.4M; Q4 positive $438k vs loss $695k.
Guidance: FY2025 revenue $126M-$130M (7-11% organic growth); expects free cash flow in H2 2025.
Post-year-end manufacturing/license deal for SimpliGraft: $1.5M upfront, minimum purchase obligations; annualized cost reductions >$5M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.